Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer.
暂无分享,去创建一个
M. Dimopoulos | C. Stefanadis | K. Toutouzas | D. Tousoulis | A. Michelongona | P. Pliatsika | F. Zagouri | M. Drakopoulou | I. Kapelakis | Aristotle Mpamias
[1] R. Ramlau,et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Berlin,et al. The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS) , 2008 .
[3] N. Kipshidze,et al. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: an experimental study. , 2007, Atherosclerosis.
[4] F. Kabbinavar,et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.
[5] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[7] C. Lindley,et al. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. , 2006, Clinical therapeutics.
[8] C. Stefanadis,et al. Advances in vulnerable plaque detection and treatment: how far have we gone? , 2006, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[9] D. Cunningham,et al. Managing Patients Treated with Bevacizumab Combination Therapy , 2005, Oncology.
[10] R. Maki,et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Berlin,et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Michael S Ewer,et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.
[14] David M Jablons,et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Qian,et al. Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias , 2004, Clinical Cancer Research.
[16] R. Dodge,et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] K. Sueishi,et al. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. , 1995, Human pathology.
[18] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[19] M. Dimopoulos,et al. Inhibition of angiogenesis: common theme for cancer and atheromatosis? , 2006, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[20] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] T. J. Poole,et al. The role of FGF and VEGF in angioblast induction and migration during vascular development , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.